Royal Bank Of Canada Exicure, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.53 - $0.84 $15 - $25	30 Added 32.26%	123 $0
Q4 2023 Feb 14, 2024	SELL	$0.37 - $0.75 $78 - $159	-213 Reduced 69.61%	93 $0
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.36 $101 - $194	143 Added 87.73%	306 $0
Q2 2023 Aug 14, 2023	BUY	$0.85 - $1.44 $70 - $119	83 Added 103.75%	163 $0
Q1 2023 May 15, 2023	BUY	$0.78 - $1.58 $4 - $9	6 Added 8.11%	80 $0
Q4 2022 Feb 14, 2023	BUY	$0.71 - $9.3 $36 - $483	52 Added 236.36%	74 $0
Q3 2022 Nov 14, 2022	BUY	$1.53 - $8.5 $33 - $187	22 New	22 $0

287K

Ticker XCUR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,962,580
Market Cap $92.7M
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.